

Selecting an Atypical Antipsychotic by Combining Clinical Experience With Guidelines From Clinical Trials

Stephen M. Stahl, M.D., Ph.D.

Three atypical antipsychotics are currently considered to be first-line therapies for schizophrenia, namely risperidone, olanzapine, and quetiapine. Deciding which one of these agents to choose for any given patient can be a daunting task because head-to-head comparisons of these 3 agents are just beginning, and most published trials are comparisons with typical antipsychotics, not with another atypical antipsychotic. Furthermore, results from clinical trials often do not match findings from clinical practice. Thus, guidelines for selection and use of the atypical antipsychotics are evolving from controlled studies as well as from clinical judgment based on the practical use of these agents once they have entered clinical practice. The atypical properties of first-line atypical antipsychotics as well as clozapine are reviewed here, with clinical pearls and dosing tips for each based upon a consensus of information from both clinical trials and clinical practice. The conventional antipsychotic loxapine is also reviewed and proposed as a potentially valuable agent to augment atypical antipsychotics when patients do not experience an acceptable treatment response from monotherapy with an atypical antipsychotic. By integrating information from clinical trials and clinical practice, the prescriber can be in a better position to choose which atypical antipsychotic to select for any given patient. (*J Clin Psychiatry* 1999;60[suppl 10]:31–41)

WHAT IS AN ATYPICAL ANTIPSYCHOTIC?

The term *atypical antipsychotic* was coined when clozapine was discovered to have properties much different from those of the conventional “neuroleptic” antipsychotics, thus appearing to be “atypical.”^{1–19} Unlike conventional antipsychotics, clozapine has a far more complex pharmacology, including serotonin-2A (5-HT_{2A}) receptor antagonist properties as well as binding to several other neurotransmitter receptors. Clinically, clozapine is atypical in that it causes surprisingly few if any extrapyramidal side effects (EPS), does not appear to cause tardive dyskinesia, does not substantially elevate prolactin, and is especially efficacious in patients who fail to respond adequately to the conventional antipsychotics (Table 1).^{3,8,20–37} Clarification of these atypical properties has spawned attempts to de-

velop novel antipsychotics with atypical properties by incorporating, at a minimum, serotonin-dopamine antagonist properties into these new drugs.

As time has progressed, the term *atypical antipsychotic* has therefore been applied to several new antipsychotic agents, and the definition of this term has evolved to mean different things to different people.^{7,8,38–40} Unfortunately, this can create confusion. For example, to a pharmacologist, *atypical antipsychotic* may mean “serotonin-dopamine antagonist” or “multiple neurotransmitter binding properties”; to a clinician worried about the side effects of an antipsychotic, it may mean “fewer EPS” or “less prolactin elevation”; to a clinician looking for optimal efficacy in schizophrenia, it may mean “better efficacy for negative symptoms” or even “better efficacy for cognitive symptoms, mood, and hostility”; to a family member of a patient with schizophrenia, it may mean “efficacy for treatment-resistant symptoms”; to a marketer, it may mean “new and different, and better than the old antipsychotics”; to a managed care formulary committee, it may mean “expensive”; and to a pharmacoeconomist, it may mean “cost-effective.”^{7,8,38–40}

Here, I will explore how 5 different antipsychotics may meet many of these criteria, for there is no universally agreed upon definition. At a minimum, *atypical antipsychotic* will be used here to mean 5-HT_{2A}-dopamine-2 (D₂) receptor antagonism coupled with reduced EPS.

From the Department of Psychiatry, University of California San Diego, and the Clinical Neuroscience Research Center, San Diego.

Presented at the closed symposium “What Makes an Antipsychotic Atypical?” which was held in Dallas, Tex., May 6–7, 1998, and was supported by an unrestricted educational grant from Watson Laboratories, Inc.

Reprint requests to: Stephen M. Stahl, M.D., Ph.D., Department of Psychiatry, University of California San Diego, and the Clinical Neuroscience Research Center, 8899 University Center Lane, Suite 130, San Diego, CA 92122.

Table 1. Clozapine: The Prototypical Atypical^a

Serotonin-dopamine antagonist?	Yes
EPS fewer than with haloperidol?	Yes
Patients essentially never get EPS?	Yes ^b
Patients essentially never get tardive dyskinesia?	Yes
Prolactin increase less than with haloperidol?	Yes
Prolactin essentially never increases?	Yes
Negative symptoms treated better than with conventional antipsychotics?	Yes
Effective for symptoms refractory to conventional antipsychotics?	Yes

^aBased on references 3, 8, and 20–37. Abbreviation: EPS = extrapyramidal side effects.
^bRare akathisia.

Table 2. Risperidone in Clinical Trials: How Does It Compare With Placebo and Haloperidol?^a

Risperidone (R; 6 mg/d) versus haloperidol (H; 20 mg/d) and placebo (PBO) in schizophrenia	
R beats H and PBO on overall psychosis ratings	
R beats H and PBO on positive symptoms	
R beats H and PBO on negative symptoms	
R beats H and PBO on cognitive symptoms	
R beats H and PBO on aggressive symptoms	
R beats H and PBO on depression/anxiety symptoms	
Conclusions	
Best efficacy outcome for a new atypical antipsychotic against haloperidol and placebo	
Doses higher than 6 mg/d not atypical in terms of EPS	
Prolactin elevations same or more than with haloperidol	

^aBased on reference 41.

Table 3. Olanzapine in Clinical Trials: How Does It Compare With Placebo and Haloperidol?^a

Olanzapine (O; ≈ 5, 10, 15 mg/d) versus haloperidol (H ≈ 15 mg/d) and placebo (PBO) in schizophrenia	
O equals H and beats PBO on overall psychosis ratings	
O equals H and beats PBO on positive symptoms	
O beats H and PBO on negative symptoms	
O beats H and PBO on anxious/depressive symptoms	
Conclusions	
Comparable efficacy to haloperidol overall and for positive symptoms, but better than haloperidol for negative symptoms and anxious/depressive symptoms	
Far more tolerable than haloperidol with occasional akathisia at low doses and much lower EPS ratings than haloperidol at high doses	
Only occasional and transient prolactin elevation, much better than haloperidol	

^aBased on references 42 and 43.

ARE THE 3 NEW ANTIPSYCHOTICS “ATYPICAL”? FINDINGS FROM CLINICAL TRIALS

Three new antipsychotics—risperidone, olanzapine, and quetiapine—have entered clinical practice since clozapine was discovered to be atypical. In terms of efficacy, Tables 2 through 4 compare published clinical trials of the new atypical antipsychotics with haloperidol in placebo-controlled studies. Risperidone, olanzapine, and quetiapine are all superior to placebo (Tables 2–4).^{41–46} There are differences, however, in how each of these 3 antipsychotics compares with haloperidol. For example,

Table 4. Quetiapine in Clinical Trials: How Does It Compare With Placebo and Haloperidol?^a

Quetiapine (Q; 75–750 mg/d) versus haloperidol (H; 12 mg/d) or placebo (PBO) in schizophrenia	
Q (150, 300, 600, and 750 mg/d) all equal H and beat PBO on overall psychosis ratings	
Q (150, 300, 600, and 750 mg/d) all equal H and beat PBO on positive symptoms	
Q (300 mg/d, but not 600 mg/d or 750 mg/d) equals H and beats PBO on negative symptoms	
Q (all doses, especially 600 mg/d) beats H and PBO on hostility/aggression	
Q (150 mg/d) beats H and PBO on anxiety/depression	
Conclusions	
Efficacy comparable to haloperidol for overall psychosis, positive symptoms, and negative symptoms	
Efficacy better than haloperidol for hostility/aggression and anxiety/depression	
Virtually no EPS observed throughout the dosing range	
Virtually no prolactin elevations, even transient, observed throughout the dosing range	
Not superior to haloperidol for negative symptoms. (However, proving greater efficacy than haloperidol in negative symptoms is more difficult for an antipsychotic with virtually no EPS, and also when compared with a low dose of haloperidol. As haloperidol dose rises, ratings of negative symptoms are raised because these symptoms are induced by the EPS that are caused at higher haloperidol doses. Thus, it is easier to beat haloperidol at high doses than at low doses. These studies used a lower dose of haloperidol than that used in studies with other atypicals.)	

^aBased on references 44–46.

although all 3 drugs are at least comparable to haloperidol, risperidone is the only drug to show efficacy superior to that of haloperidol for positive symptoms, and quetiapine is the only drug that fails to show efficacy superior to that of haloperidol for negative symptoms. Whether this translates into meaningful differences in clinical practice remains to be determined, because reported differences between an atypical antipsychotic and haloperidol in any given clinical trial can also be due to simple variability between trials, use of different rating instruments, type of statistics employed, and differences in the doses chosen both for haloperidol and for the new antipsychotic.

The conclusions as to whether each of the 3 new antipsychotics is atypical—and by which criteria—are given in Tables 5 through 7. Note that the degree of atypicality differs from one drug to another depending upon the factor of atypicality chosen and the quality of the evidence that exists so far. Available literature for risperidone,^{41,47–91} olanzapine,^{42,43,92–127} and quetiapine^{44–46,128–137} was reviewed and is summarized in Tables 5–7.

OLD WINE IN A NEW BOTTLE? LOXAPINE IS A SEROTONIN-DOPAMINE ANTAGONIST, YET A CONVENTIONAL ANTIPSYCHOTIC

Loxapine is known as a conventional antipsychotic, but has recently been discovered to have 5-HT_{2A} antagonist properties like clozapine and the 3 new atypical antipsy-

Table 5. Risperidone: Is It Atypical?^a

Serotonin-dopamine antagonist?	Yes
EPS fewer than with haloperidol?	Yes ^b
Patients essentially never get EPS?	No ^b
Reduced incidence of tardive dyskinesia?	Probably
Prolactin increase less than with haloperidol?	No ^c
Negative symptoms better than placebo?	Yes
Negative symptoms treated better than with 20 mg of haloperidol?	Yes
Effective for symptoms refractory to conventional antipsychotics?	Maybe

^aBased on references 41 and 47–91.

^bAt low doses, EPS same as with placebo but occasionally seen; at high doses, EPS increased, but still fewer than with haloperidol.

^cProlactin increases same or more than with haloperidol.

Table 6. Olanzapine: Is It Atypical?^a

Serotonin-dopamine antagonist?	Yes
EPS fewer than with haloperidol?	Yes
Patients essentially never get EPS?	Yes and no ^b
Reduced incidence of tardive dyskinesia?	Probably
Prolactin increase less than with haloperidol?	Yes
Prolactin essentially never increases?	No ^c
Negative symptoms treated better than with placebo?	Yes
Negative symptoms treated better than with about 15 mg of haloperidol?	Yes
Effective for symptoms refractory to conventional antipsychotics?	Maybe

^aBased on references 42, 43, and 92–127.

^bEPS unusual except occasional akathisia at up to 15 mg/d, but EPS occasionally seen at doses above usual prescribing range (ie, > 15 mg/d).

^cProlactin elevations in fewer patients compared to haloperidol and usually transient.

Table 7. Quetiapine: Is It Atypical?^a

Serotonin-dopamine antagonist?	Yes
EPS fewer than with haloperidol?	Yes
Patients essentially never get EPS?	Yes
Reduced incidence of tardive dyskinesia?	Expected ^b
Prolactin increase less than with haloperidol?	Yes
Prolactin essentially never increases?	Yes
Negative symptoms treated better than with placebo?	Yes
Negative symptoms treated better than with 12 mg of haloperidol?	No ^c
Effective for symptoms refractory to conventional antipsychotics?	Maybe

^aBased on references 44–46 and 128–137.

^bStudies in progress.

^cThe lower the dose of haloperidol, and the fewer EPS caused by an atypical, the harder it may be to beat haloperidol due to the lack of haloperidol-induced negative symptoms at low doses.

chotics risperidone, olanzapine, and quetiapine.³⁹ Because it was introduced prior to the discovery of clozapine's atypical antipsychotic properties, why wasn't loxapine the first atypical antipsychotic?

Firstly, all atypical antipsychotics are serotonin-dopamine antagonists, but this does not mean that every serotonin-dopamine antagonist will be an atypical antipsychotic. Indeed, Tables 1–7 show that the known serotonin-dopamine antagonists may differ substantially on the various factors of atypicality. On the other hand, loxapine was tested in a prior era, with trials not designed to show supe-

Table 8. Loxapine: How Does It Compare With Conventional Antipsychotics?^a

No fixed-dose comparative trials
 No consistent differences between loxapine and conventional antipsychotics, but in 5 comparison studies with haloperidol, EPS comparable to haloperidol at generally higher doses of loxapine in 3 studies and EPS fewer than with haloperidol at generally lower doses of loxapine in 2 studies
 No study of negative symptoms. However, of 21 older studies comparing loxapine and a conventional antipsychotic using older rating scales (BPRS and NOSIE), 6 showed statistically superior efficacy for loxapine on negative symptom–related items, 14 showed no differences, and 1 showed superiority of a comparator over loxapine
 No treatment-refractory studies, but study of loxapine augmentation for 18–52 weeks of 7 clozapine partial responders after 9 months of clozapine treatment showed no change in blood clozapine levels, with all patients improving somewhat, 2 improving remarkably

Conclusions

Typical properties of a conventional antipsychotic in recommended dosage range of 60–250 mg/d
 Efficacy comparable to haloperidol for overall psychosis and for positive symptoms
 No clearly atypical features in the recommended dosage range, but EPS may be fewer than with haloperidol, although prolactin elevations same as with haloperidol
 Inadequate studies of negative symptoms and treatment-refractory patients
 No low-dose studies in the 5- to 50-mg/d range, where it may hypothetically have potentially atypical properties

^aBased on references 1, 7, 8, 38–40, and 138–184. Abbreviations: BPRS = Brief Psychiatric Rating Scale, NOSIE = Nurses' Observation Scale for Inpatient Evaluation.

Table 9. Loxapine: Is It Atypical?^a

Serotonin-dopamine antagonist?	Yes
EPS fewer than with haloperidol?	Maybe ^b
Patients essentially never get EPS?	No ^c
Reduced incidence of tardive dyskinesia?	No ^c
Prolactin increase less than with haloperidol?	No ^c
Negative symptoms treated better than with placebo?	Maybe ^d
Negative symptoms treated better than with haloperidol?	Maybe ^d
Effective for symptoms refractory to conventional antipsychotics?	Maybe ^e

^aBased on references 1, 7, 8, 38–40, and 138–184.

^bSome but not all studies show lower EPS than with haloperidol.

^cEPS and elevated prolactin at doses of 60 mg/d or more; no studies less than 20 mg/d.

^dNo proper study of negative symptoms, but some studies show lower negative symptom–related items than with conventional antipsychotics.

^eNo monotherapy study, but improved symptoms unresponsive to clozapine when loxapine added as an augmenting agent.

rity to haloperidol in terms of EPS, efficacy for negative symptoms, or efficacy for treatment-refractory symptoms. Furthermore, Glazer's⁴⁰ retrospective review of loxapine's potentially atypical properties indeed provides some hints of atypicality. Since loxapine may have efficacy at low doses, it is possible that atypical properties may be more prominent if lower doses are used. Is loxapine the "Cinderella" antipsychotic awaiting invitation to the low-dose atypical ball?

This is only a hypothetical possibility that must await further investigation. Currently, it is prudent to consider

Table 10. Risperidone Versus Olanzapine in Head-to-Head Clinical Trials^a

Measure	Lower Dose Trial ^b (R ≈ 4.8 mg/d; O ≈ 12.5 mg/d)	Higher Dose Trial ^c (R ≈ 7.2 mg/d; O ≈ 17.2 mg/d)
Efficacy		
Overall psychosis ratings ^d	R = O	R = O
Positive symptoms	R beats O	R = O
Negative symptoms	R = O	O beats R
Cognitive symptoms ^d	R = O	R = O
Aggressive symptoms ^d	R = O	R = O
Depression/anxiety	R beats O	R = O
Response maintenance	Not reported	O beats R
Response rate	R beats O (for > 30% response)	O beats R (for > 40% response)
Side effect		
EPS	R = O	O beats R
Weight gain ^d	R beats O	R beats O
Prolactin ^d	O beats R	O beats R
Conclusions		
Dose matters		
Two conflicting trials require independent replication for a tie-breaker		
Risperidone may be a better drug at lower doses; olanzapine may be a better drug at higher doses		

^aThese are the only 2 head-to-head placebo-controlled trials of 2 atypical antipsychotics (both atypicals beat placebo).

^bSponsored by Janssen Pharmaceutica Inc. (see reference 53).

^cSponsored by Eli Lilly and Company (see reference 107).

^dWhere both trials agree.

loxapine to be a bit unusual perhaps, but still a conventional antipsychotic as it is normally used in clinical practice. The findings for loxapine from clinical trials and an overview of the status of its potentially atypical properties are given in Tables 8 and 9. Literature reviewed for loxapine was collated for Tables 8 and 9.^{1,7,8,38-40,138-184}

IS ONE ATYPICAL ANTIPSYCHOTIC SUPERIOR TO ANOTHER? LIES, DAMN LIES, AND STATISTICS FROM CLINICAL TRIALS

Most published clinical trials for the atypical antipsychotics are studies of one atypical versus one conventional antipsychotic, usually haloperidol. Head-to-head comparisons of 2 atypical antipsychotics in placebo-controlled multicenter trials are just now emerging. Two studies have been presented comparing risperidone with olanzapine and have generated considerable controversy (Table 10).^{53,107} There are no published head-to-head placebo-controlled comparisons between quetiapine and either risperidone or olanzapine.

The problem of relying on head-to-head comparisons of 2 drugs as a basis for choosing to prescribe one over the other is exemplified by the situation, shown in Table 10, where 2 different studies purport to compare risperidone with olanzapine. The results of these 2 clinical trials of the same atypical antipsychotics can seem to say opposite things, depending upon one's perspective. In one study, risperidone appears to have efficacy superior or equal to

Table 11. Findings From Clinical Practice That Confirm Clinical Trials

Atypicals undoubtedly cause fewer EPS compared with conventionals
Atypicals probably reduce negative symptoms of schizophrenia better than the conventionals, but this may in part be secondary to fewer EPS
Atypicals possibly reduce cognitive and affective symptoms in schizophrenia, which may also be secondary to fewer EPS
The magnitude of these properties makes atypicals first-line therapies for psychosis, and conventional antipsychotics second-line

Table 12. Perceptions From Clinical Practice That Differ From Clinical Trials

Different atypical antipsychotics often have clinically distinctive effects in different patients (unlike conventional antipsychotics)
Optimal doses derived from clinical trials do not match optimal doses used in clinical practice
Atypical antipsychotics do not always seem to work as fast as conventional antipsychotics
Atypical antipsychotics can appear to be less effective than conventional antipsychotics in treating acute psychosis, especially in the first few days
Atypical antipsychotics can appear to be less effective than conventional antipsychotics in treating agitation (especially if acute)
Efficacy of new atypical antipsychotics in treating patients refractory to conventional antipsychotics is not dramatic. Clozapine is still the gold standard
To switch from ongoing treatment to a new drug, some clinical trials recommended "stop-start," whereas in practice, patients are usually "cross-tapered" (ie, the immediate discontinuation of ongoing treatment followed by the immediate starting of a new atypical drug can lead to rebound psychosis, withdrawal reactions, and rehospitalizations. Instead, the dose of ongoing treatment can be tapered down, while the dose of the new atypical drug is simultaneously tapered up.)
Occasional patients may actually respond better to conventional antipsychotics than to atypical antipsychotics

that of olanzapine, whereas in the other, olanzapine seems to have efficacy superior or equal to that of risperidone.

What is the meaning of these results? The answer may lie in the different doses selected, because risperidone seems to look more efficacious at low doses, whereas olanzapine seems to look more efficacious at high doses. The studies agree only in the area of side effects: both find more prolactin elevation with risperidone and more weight gain with olanzapine.

Statistically significant differences between 2 drugs in how they improve certain symptoms in a population of patients may not meaningfully translate into clinically significant differences between these same 2 drugs for any given individual patient. Indeed, interindividual variation is often much greater than the size of the mean differences between 2 large groups derived from clinical trials. The randomized trial is capable of showing that 2 outcomes are different from each other. However, these trials do not always show differences of a magnitude and consistency that provide clear guidelines on how to select one atypical antipsychotic over another for any given individual patient. Thus, these findings in Table 10 should be weighed in the

Table 13. Factors in Choosing an Atypical Antipsychotic: Weight Gain^a

No change or weight loss
Loxapine
Molindone
Increasing likelihood of weight gain
Ziprasidone (the least weight gain)
Thiothixene
Fluphenazine
Haloperidol
Risperidone
Chlorpromazine
Sertindole
Quetiapine
Thioridazine
Olanzapine
Zotepine
Clozapine (the most weight gain)

^aBased on references 72–78.

Table 14. Frequency of Augmentation of an Atypical Antipsychotic With a Second Antipsychotic in Clinical Practice^a

Drug	% of All Prescriptions
Risperidone	
Survey 1	4.2
Survey 2	4.6
Survey 3	7.1
Olanzapine	
Survey 1	25.1
Survey 2	15.4
Survey 3	6.1
Quetiapine	
Survey 1	11.4
Survey 2	21.5
Survey 3	6.4
Clozapine	
Survey 1	9.7
Survey 2	12.5
Survey 3	12.3

^aSurvey 1: National Disease and Therapeutic Index (NDTI) survey for the second quarter of 1998, IMS HEALTH, Plymouth Meeting, Pa.; Survey 2: NDTI survey for the third quarter of 1998, IMS HEALTH, Plymouth Meeting, Pa.; Survey 3: Scott-Levin Physician Drug & Diagnosis Audit (PDDA) for the third quarter of 1998, Scott-Levin, a division of PMSI Scott-Levin, Inc.

selection of risperidone versus olanzapine, but other factors outlined below should also factor into that decision.

AN OVERVIEW OF ATYPICAL ANTIPSYCHOTICS IN CLINICAL PRACTICE

Tables 2, 3, 4, and 10 have summarized results from clinical trials of the atypical antipsychotics. As there has now been considerable experience with each of these drugs in clinical practice, it may be useful to review the areas of agreement and disagreement between clinical trials and clinical practice. These are summarized in Tables 11 and 12. Specific information from clinical practice that applies to 5 antipsychotic drugs will be detailed in the following section. These drugs are clozapine, risperidone, olanzapine, quetiapine, and loxapine.

Table 15. Choice of Augmenting Agent When Coprescribing Atypical Antipsychotics With a Second Antipsychotic in Clinical Practice^a

Drug	Distribution of Antipsychotic Cotherapy From Table 14	
	% Augmentation With Conventional	% Augmentation With 2nd Atypical
Risperidone		
Survey 1	88	12
Survey 2	70	30
Survey 3	55	45
Olanzapine		
Survey 1	83	17
Survey 2	34	66
Survey 3	91	9
Quetiapine		
Survey 1	50	50
Survey 2	17	83
Survey 3	25	75
Clozapine		
Survey 1	0	100
Survey 2	43	57
Survey 3	26	74

^aSurvey 1: NDTI survey for the second quarter of 1998, IMS HEALTH, Plymouth Meeting, Pa.; Survey 2: NDTI survey for the third quarter of 1998, IMS HEALTH, Plymouth Meeting, Pa.; Survey 3: Scott-Levin PDDA for the third quarter of 1998, Scott-Levin, a division of PMSI Scott-Levin, Inc.

Weight is often ignored by clinicians, with body weight and body mass index not monitored during long-term treatment. Since many of the atypical antipsychotics in frequent use may increase body weight by 20 to 50 lb (9–22 kg) with long-term maintenance, the selection of an atypical antipsychotic may be influenced by its actual or potential effects on weight gain (Table 13).^{72–78} Regardless of which antipsychotic is chosen, monitoring body weight and preventing obesity should be a priority for antipsychotic prescribers. New data document better than ever the increased health risks of obesity, such as new-onset diabetes mellitus and especially accelerated cardiovascular mortality. This may be particularly relevant for the treatment of schizophrenic patients who are likely to have disproportionately high levels of other cardiovascular risk factors such as smoking (up to 80% of schizophrenic patients), sedentary lifestyle, and unhealthy diet.

Although clinical trials are conducted in patients taking only one antipsychotic drug, in practice up to one fourth of patients are taking 2 (Tables 14 and 15). The data in Tables 14 and 15 come from prescription surveys, with the first a National Disease Therapeutic Index (NDTI) survey for the second quarter of 1998 (IMS HEALTH, Plymouth Meeting, Pa.), the second an NDTI survey for the third quarter of 1998 (IMS HEALTH, Plymouth Meeting, Pa.), and the third a Physician Drug & Diagnosis Audit (PDDA) for the third quarter of 1998 (Scott-Levin, a division of PMSI Scott-Levin, Inc.). Physicians were surveyed concerning all concomitant medications that they gave with each atypical antipsychotic they prescribed. The frequency of

Table 16. Factors in Choosing an Atypical Antipsychotic: Managing Inadequate Treatment Responses to Antipsychotic Drugs

Monotherapy with an atypical is considered to be inadequate in up to 20% of patients who also receive augmentation with a second antipsychotic drug
 If one of these 3 atypical agents (risperidone, olanzapine, quetiapine) generates an unsatisfactory treatment response at normal doses, try one of the other atypical antipsychotics before augmenting
 If the second drug is also unsatisfactory, try the third
 If all 3 atypicals are unsatisfactory, consider higher doses than usual, a trial of clozapine, or various augmentation strategies
 Augmentation can be with a conventional antipsychotic such as loxapine or haloperidol, with a benzodiazepine such as lorazepam, or with a mood stabilizer such as valproic acid

Table 17. Clozapine Pearls^a

Most efficacious but most dangerous
 May reduce violence and aggression in difficult cases
 Reduces suicide in schizophrenia
 May improve tardive dyskinesia
 Clinical improvements may continue slowly over several years
 Not a first-line/first-break treatment choice in most countries
 Can cause agranulocytosis (0.5%–2%)
 Requires monitoring of blood counts weekly for 6 months, then every 2 weeks
 Dose-related increased risk of seizures
 Over 550 mg/d may require concomitant anticonvulsant
 Can cause significant weight gain
 Sedation and sialorrhea (especially at night) may be bothersome

^aBased on references 3, 8, and 19–37.

Table 18. Risperidone Pearls^a

Well accepted for treatment of agitation and aggression in elderly demented patients
 Well accepted for treatment of bipolar disorders
 Many anecdotal reports of utility in children, treatment-refractory cases, and for positive symptoms of psychosis in disorders other than schizophrenia
 Only atypical antipsychotic that elevates prolactin levels, but this is of unproven and uncertain clinical significance
 Although low doses cause no more EPS than placebo, that does not mean they never cause EPS
 Less weight gain than some other antipsychotics, but this does not mean no weight gain

^aBased on references 8, 41, and 47–91.

use of another antipsychotic in these surveys is given in Table 14. The breakdown as to how many of these prescriptions were for a conventional antipsychotic or for another atypical antipsychotic is given in Table 15.

Whether the concomitant administration of 2 antipsychotic drugs in the patients from these surveys is rational (due to poor treatment response to an atypical antipsychotic) or irrational polypharmacy is not represented in these tables. Presumably there is some of both. Given that treatment nonresponsiveness is well documented in 5% to 25% of schizophrenic patients,^{27,31} however, the numbers deriving from clinical practice are consistent with use of 2 antipsychotics for patients who have an unsatisfactory treatment response to an atypical antipsychotic. These surveys

Table 19. Risperidone Dosing Tips^a

Less may be more: By lowering dose, side effects often reduced without loss of efficacy
 Thus, doses used in clinical practice are *lower* than doses suggested from early clinical trials
 Target dose for best efficacy/best tolerability may be 2–6 mg/d (average = 4.5 mg/d) except in children or elderly, who should get 0.5–2.0 mg/d
 Patients who respond to these doses may have lowest drug costs among the atypicals
 Low doses may not be adequate in difficult patients
 Rather than raise dose above these levels in agitated patients, in partial responders, or in acutely ill patients requiring sudden antipsychotic effects, consider augmentation with a benzodiazepine or conventional antipsychotic, orally or i.m.
 Can use once-daily dosing
 May wish to use twice-daily dosing for the elderly and children during dosage titration
 Only atypical antipsychotic with liquid dosage formulation
 Tablets as small as 0.25 mg and 0.5 mg soon available
 Working on new formulation that dissolves on tongue
 Working on depot palmitate formulation for monthly administration of 9-hydroxy metabolite
 Compliance monitoring at point of care for presence of drug in saliva or urine available soon

^aBased on references 8, 41, and 47–91.

Table 20. Olanzapine Pearls^a

Well accepted for use in schizophrenia and bipolar disorders, including difficult cases
 Many anecdotal reports of utility in children, treatment-refractory cases, and for positive symptoms of psychosis in disorders other than schizophrenia
 Documented efficacy as augmenting agent to SSRIs in nonpsychotic treatment-resistant major depressive disorder
 Muscarinic antagonist properties theoretically unfavorable for cognition in schizophrenia, and in the elderly, but cognitive symptoms of schizophrenia may improve in some clinical trials
 Same EPS as placebo does not mean never, but EPS unusual at low to mid doses
 More weight gain than other antipsychotics does not mean every patient gains weight
 Not necessary to monitor liver function tests except in significant liver disease

^aBased on references 8, 42, 43, and 92–127. Abbreviation: SSRI = selective serotonin reuptake inhibitor.

excluded patients being tapered or cross-tapered with one of these agents.

It is a sorry fact that there are no large-scale studies of which patients are most likely to benefit from an atypical antipsychotic augmented with a second antipsychotic. It is not known whether patients receiving an atypical antipsychotic with a conventional antipsychotic would be better off on treatment with the conventional antipsychotic alone. It is not known whether the use of 2 atypicals simultaneously (from 9% to 100% of the time depending upon the survey; see Table 15) is cost-effective, especially considering that use of 2 atypical agents can double or quadruple the cost of drug therapy. Studies are sorely needed to determine a rational approach to treatment with 2 antipsychotics that has a positive risk-benefit ratio and that is also cost-effective. Until these studies are available, it

Tables 21. Olanzapine Dosing Tips^a

More may be more: By raising dose above recommended levels of 15 mg/d, can be useful for acutely ill and agitated patients, and even some treatment-resistant patients, gaining efficacy without many more side effects

Thus, doses used in clinical practice (> 15 mg/d) often *higher* than those suggested from clinical trials (ie, usually 10 mg/d)

Patients who respond to higher doses will have higher drug costs, but this may be justified if the patient is severely ill and other options fail

Higher doses given in the acute period or while agitated can sometimes be reduced later when patient stabilized

Rather than raising doses to high level in difficult cases, consider augmentation with a benzodiazepine or conventional antipsychotic orally or i.m.

Women may require lower doses than men since plasma levels higher in women than in men at comparable doses

Once-daily administration for all applications

4 dose sizes: 2.5 mg, 5 mg, 7.5 mg, and 10 mg

No scored tablets, so cannot break in half

Each tablet costs about the same, so a single dose size will allow 2.5, 5, 7.5, or 10 mg/d; price can double for 2 dosage sizes (required for 12.5, 15, 17.5, or 20 mg/d); price can triple for 3 dosage sizes (required for 22.5, 25, 27.5, or 30 mg/d)

A 15-mg and a 20-mg tablet may become available to reduce drug costs

An i.m. dosage formulation for acute administration is in development

^aBased on references 8, 42, 43, and 92–127.

Table 22. Quetiapine Pearls^a

Some patients respond to quetiapine who have failed to respond to other atypicals

Anecdotal reports of usefulness for treatment-refractory cases, bipolar disorder, and for positive symptoms of psychosis in disorders other than schizophrenia

Early studies support use in adolescents, elderly, and for hostility/aggression, cognition, and affective symptoms in schizophrenia

Beats placebo (but not haloperidol) on negative symptoms, yet least likely to cause negative symptoms secondary to EPS

Never say never, but essentially no EPS or prolactin elevation at any dose

Cataracts caused at high doses in dogs but not monkeys or humans, possibly due to species-specific inhibition of cholesterol biosynthesis in the lens of dogs

However, in US, FDA precaution to monitor for development of cataracts every 6 months (similar to precaution for carbamazepine and HMGCoA reductase inhibitors of cholesterol biosynthesis)

Not necessary to get eye exams until dose stabilized and planned for long-term use

^aBased on references 8, 44–46, and 128–137.

would be prudent to use 2 antipsychotics reluctantly and only for patients whose inadequate treatment responses to a single atypical antipsychotic are clearly improved by the addition of a second antipsychotic. Judicious use of low doses of a conventional antipsychotic added on to the most cost-effective dose of an atypical antipsychotic is the most inexpensive approach. Given the pharmacologic properties of loxapine, and numerous case reports of its enhancement of clozapine efficacy, this agent, particularly in low doses, should be considered when augmentation of an atypical antipsychotic with another antipsychotic is being tried (Table 16).

Table 23. Quetiapine Dosing Tips^a

Clinical trials suggest effective dose range is 75–400 mg bid for schizophrenia (except lower doses in the elderly, namely 25–75 mg bid)

Clinical practice suggests target doses of 150–200 mg bid for schizophrenia

Some clinical trials done tid, but in clinical practice, doses are given bid, and may even transition to once daily, especially for total daily doses of 400 mg or less, and after stabilized for long-term treatment

More may be more: Raising dose can be useful for acutely ill and agitated patients, and even some treatment-resistant patients, gaining efficacy without essentially any more side effects, especially over 200 mg bid

3 dose sizes: 25, 100, and 200 mg

No scored tablets so cannot break in half

Recommended titration to 300–400 mg/d by the fourth day requires 2 doses/d and changing combinations of 25-mg, 100-mg, and 200-mg tablets

In practice, aim for 200 mg bid on the fifth day, whether initiating new patients or switching while cross-titrating down with another antipsychotic, eg, 50 mg on day 1 (25 mg bid or 50 mg qhs), 150 mg on day 2 (50 mg q am and 100 mg qhs), 200 mg on day 3 (100 mg bid), 300 mg on day 4 (100 mg q am and 200 mg qhs), and 400 mg on day 5 (200 mg bid); this regimen uses a total of four 25-mg tablets, four 100-mg tablets, and one 200-mg tablet in the first 4 days, then two 200-mg tablets daily thereafter

At 200 mg bid may be a lower cost atypical, but other doses higher or lower may be more expensive (more than twice the cost) and require complicated combinations of multiple tablets and multiple dosage sizes (up to 10 tablets/d and all 3 dosage strengths)

^aBased on references 8, 44–46, and 128–137.

Table 24. Loxapine Pearls^a

Recently discovered to be a serotonin-dopamine antagonist (binding studies and PET scans)

Active metabolites also serotonin-dopamine antagonists

Developed as a conventional antipsychotic, ie, reduces positive symptoms, but causes EPS and prolactin elevations

Lower EPS than haloperidol in some studies, but no fixed-dose studies and no low-dose studies

Causes less weight gain than other antipsychotics, both atypical and conventional, and may even be associated with weight loss

Norepinephrine reuptake blocking properties suggest potential utility for depressive symptoms

No formal studies of negative symptoms, but some studies show superiority to conventional antipsychotics for emotional withdrawal and social competence

Best use may be as a low-cost augmentation agent to atypical antipsychotics, eg, enhances efficacy in clozapine partial responders when given concomitantly with clozapine

For previously stabilized patients with “breakthrough” agitation or incipient decompensation, “top up” the atypical antipsychotic with prn i.m. or oral single doses of loxapine

For patients maintained on 2 antipsychotics, use loxapine to augment 1 atypical

For the greater than one third of patients on doses of an atypical antipsychotic above the documented atypical/cost-effective ranges, consider lowering atypical antipsychotic dose and augmenting with loxapine 5–60 mg/d

Loxapine has only 10%–25% the cost of atypical antipsychotics

^aBased on references 1, 8, and 138–184.

**LIES, DAMN LIES, AND IN MY CLINICAL JUDGMENT:
CLINICAL PEARLS AND DOSING TIPS
FOR ANTIPSYCHOTICS**

In this section, clinical pearls and dosing tips derived both from clinical trial experience and from the effects of

Table 25. Loxapine Dosing Tips^a

Has conventional antipsychotic properties at originally recommended doses (ie, starting at 10 mg bid, maintenance 60–100 mg/d, maximum 250 mg/d given in divided doses)

Binding studies, PET studies, and anecdotal clinical observations suggest that loxapine may be atypical at lower doses (perhaps 5–60 mg/d), but further studies needed

Anecdotal evidence that many patients can be maintained at 20–60 mg/d as monotherapy

Available as 5-mg and 10-mg capsules for low-dose use and as 25-mg and 50-mg capsules for routine use

Available as a liquid dosage formulation

Only serotonin-dopamine antagonist available for acute intramuscular administration (50 mg/mL)

Loxapine i.m. may have faster onset of action and superior efficacy for agitated/excited and aggressive behavior than i.m. haloperidol

Give 25–50 mg i.m. (0.5–1.0 mL of 50 mg/mL solution) with onset of action within 60 minutes in the acute situation

When initiating therapy with an atypical antipsychotic in an acute situation, consider i.m. loxapine to “lead in” to orally administered atypical; eg, initiate oral dosing of an atypical antipsychotic with 25–50 mg loxapine bid to tid i.m. short-term as necessary for antipsychotic effects without EPS and sedation

When using loxapine to “top up” previously stabilized patients now decompensating, may use loxapine as single 25- to 50-mg doses prn as i.m., or oral liquid or tablets

To augment partial responders to an atypical antipsychotic, consider doses of loxapine as low as 5–60 mg/d, but use full doses if necessary

^aBased on references 1, 8, and 138–184.

atypical antipsychotics in clinical practice are detailed in several tables. These include clozapine (Table 17),^{3,8,19–37} risperidone (Tables 18 and 19),^{8,41,47–91} olanzapine (Tables 20 and 21),^{8,42,43,92–127} quetiapine (Tables 22 and 23),^{8,44–46,128–137} and loxapine (Tables 24 and 25).^{1,8,138–184}

SUMMARY

In summary, combining statistics and science from clinical trials with art and anecdote from clinical practice may assist the prescriber in selecting an atypical antipsychotic.

Drug names: carbamazepine (Tegretol and others), chlorpromazine (Thorazine and others), clozapine (Clozaril), fluphenazine (Prolixin and others), haloperidol (Haldol and others), lorazepam (Ativan and others), loxapine (Loxitane and others), molindone (Moban), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), thioridazine (Mellaril and others), thiothixene (Navane), valproic acid (Depakene and others).

REFERENCES

- Baldessarini RJ. Drugs and the treatment of psychiatric disorders: psychosis and anxiety. In: Goodman and Gilman's Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw Hill Press; 1996:399–430
- Marder SR. Antipsychotic medications. In: Schatzberg AF, Nemeroff CB, eds. Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1998:309–322
- Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994;55(9, suppl B):47–52
- Meltzer HY. Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1996:1277–1286
- Schatzberg AF, Nemeroff CB, eds. Textbook of Psychopharmacology. 2nd

- ed. Washington, DC: American Psychiatric Press; 1998
- Stahl SM. Essential Psychopharmacology. New York, NY: Cambridge University Press; 1996
- Stahl SM. What makes an antipsychotic atypical? [BRAINSTORMS] J Clin Psychiatry 1998;59:2–3
- Stahl SM. Psychopharmacology of Antipsychotics. London, England: Martin Dunitz; 1999
- Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996;57(suppl 11):4–11
- Leysen JE, Janssen PMF, Heylen L, et al. Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects. Int J Psychiatry Clin Pract 1998;2(suppl 1):S3–S18
- Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? a review of the evidence. Neuropsychopharmacology 1998;18:63–101
- Kapur S, Remington G. Serotonin dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466–476
- Kapur S. 5-HT₂ antagonism and EPS benefits: is there a causal connection? Psychopharmacology 1996;124:35–39
- Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996;124:2–34
- Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D₁, D₂ and serotonin 2 pKi values. J Pharmacol Exp Ther 1989;251:238–246
- Roth BL, Tandra S, Burgess LH, et al. D₄ dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 1995;120:355–368
- Roth BL, Craido FC, Choudhary MF, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxy tryptamine 6 and 5-hydroxy tryptamine 7 receptors. J Pharmacol Exp Ther 1994;268:1403–1410
- Seeman P, Corbett R, VanPol HHM. Atypical neuroleptics have no affinity for dopamine D₂ receptors or are selective for D₄ receptors. Neuropsychopharmacology 1997;16:93–110
- Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin 2 and dopamine 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989;25:390–392
- Murray RM, Van Os J. Predictors of outcome in schizophrenia. J Clin Psychopharmacol 1998;18(suppl 1):2S–4S
- Meltzer HY, Lee M, Cola P. The evolution of treatment resistance: biological implications. J Clin Psychopharmacol 1998;18(suppl 1):5S–11S
- Sharma T, Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. J Clin Psychopharmacol 1998;18(suppl 1):12S–19S
- Lieberman JA, Sheitman B, Chakos M, et al. The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. J Clin Psychopharmacol 1998;18(suppl 1):20S–24S
- Nordstrom AL, Farde L, Halldin C. High 5-HT₂ receptor occupancy in clozapine-treated patients demonstrated by PET. Psychopharmacology 1993;110:365–367
- Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989;50:329–338
- Grohmann R, Schmidt LG, Spieb-Kiefer C, et al. Agranulocytosis and significant leukopenia with neuroleptic drugs: results from the AMUP program. Psychopharmacology 1989;99:S109–S112
- Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789–796
- Meltzer HY. Dopaminergic and serotonergic mechanisms and the action of clozapine. In: Tamminga CA, Schulz SC, eds. Advances in Neuropsychiatry and Psychopharmacology, vol 1. New York, NY: Raven Press; 1991:333–340
- Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59(suppl 3):3–7
- Glazer WM, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry 1998;59(suppl 3):8–14
- Treatment-Resistant Schizophrenia: The Importance of Early Detection and Treatment. J Clin Psychopharmacol 1998;18(suppl 1):1S–24S
- Casey DE. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J Clin Psychiatry 1998;59(suppl 3):31–37
- Lieberman JA. Maximizing clozapine therapy: managing side effects. J Clin Psychiatry 1998;59(suppl 3):38–43
- Conley RR. Optimizing treatment with clozapine. J Clin Psychiatry 1998;59(suppl 3):44–48

35. Macgibbon GA, Lawlor PA, Bravo R, et al. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate putamen, nucleus accumbens, lateral septum, and islands of Calleja. *Mol Brain Res* 1994;23:21–32
36. Trichard C, Paillere-Martinot ML, Attar-Levy D, et al. Binding of antipsychotic drugs to cortical 5-HT_{2A} receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. *Am J Psychiatry* 1998;155:505–508
37. Meltzer HY. Suicide in schizophrenia: risk factors and clozapine treatment. *J Clin Psychiatry* 1998;59(suppl 3):15–20
38. Remington G, Kapur S. D₂ and 5-HT₂ receptor effects of antipsychotics: bridging basic and clinical findings using PET. *J Clin Psychiatry* 1999;60(suppl 10):15–19
39. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. *J Clin Psychiatry* 1999;60(suppl 10):5–14
40. Glazer WM. Does loxapine have “atypical” properties? clinical evidence. *J Clin Psychiatry* 1999;60(suppl 10):42–46
41. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. *J Clin Psychiatry* 1997;58:538–546
42. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. *Neuropsychopharmacology* 1996;14:111–123
43. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. *Arch Gen Psychiatry* 1998;55:250–258
44. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. *Biol Psychiatry* 1997;42:233–246
45. Cantillio M, Goldstein JM. Quetiapine fumarate reduces aggression and hostility in patients with schizophrenia. In: New Research Program and Abstracts of the 151st Annual Meeting of the American Psychiatric Association; June 3, 1998; Toronto, Ontario, Canada. Abstract NR444:188
46. Goldstein JM. Quetiapine fumarate: effects of hostility, aggression and affective symptoms in patients with acute schizophrenia. Presented at the 38th annual meeting of the New Clinical Drug Evaluation Unit; June 10–15, 1998; Boca Raton, Fla
47. Lussier I, Stip E. The effect of risperidone on cognitive and psychopathological manifestations of schizophrenia. *CNS Spectrums* 1998;3:55–69
48. Kelly DL, Conley RR, Love RC, et al. Dose-outcome analysis of risperidone. Presented at the 37th annual meeting of the American College of Neuropsychopharmacology; Dec 14–18, 1998; Las Croabas, Puerto Rico
49. Nelson MW, Kelley DL, Love RC, et al. Risperidone versus olanzapine: discharge rates and economic considerations. Presented at the 37th annual meeting of the American College of Neuropsychopharmacology; Dec 14–18, 1998; Las Croabas, Puerto Rico
50. Byerly MJ, DeVane L. Pharmacokinetics of clozapine and risperidone: a review of recent literature. *J Clin Psychopharmacol* 1996;16:177–187
51. Chung Y-C, Eun H-B. Hyperprolactinaemia induced by risperidone. *Int J Neuropsychopharmacol* 1998;1:93–94
52. Chouinard G, Jones BJ, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. *J Clin Psychopharmacol* 1993;13:25–40
53. Conley RR, Brecher M, and the Risperidone/Olanzapine Study Group. Risperidone versus olanzapine in patients with schizophrenia or schizoaffective disorder. Presented at the 11th annual meeting of the Congress of the European College of Neuropsychopharmacology; Oct 31–Nov 4, 1998; Paris, France
54. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. *Can J Psychiatry* 1993;38(suppl 3):S80–S88
55. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. *Am J Psychiatry* 1994;151:825–835
56. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. *Br J Psychiatry* 1995;166:712–726
57. Gelenberg AJ, Hopkins HS. Antipsychotics in bipolar disorder. *J Clin Psychiatry* 1996;57(suppl 9):49–52
58. Bondolfi G, Dufour H, Patris M, et al, on behalf of the Risperidone Study Group. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. *Am J Psychiatry* 1998;155:499–504
59. Kleinberg DL, Brecher M, Davis JM. Prolactin levels and adverse events in patients treated with risperidone. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 21, 1997; San Diego, Calif. Abstract NR599:229
60. Kee KS, Kern RS, Marshall BD Jr, et al. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. *Schizophr Res* 1998;31:159–165
61. Green MF, Marshall BD Jr, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? *Am J Psychiatry* 1997;154:799–804
62. Lindenmayer J-P, Iskander A, Park M, et al. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. *J Clin Psychiatry* 1998;59:521–527
63. Tracy JL, Monaco CA, Abraham G, et al. Relation of serum anticholinergic activity to cognitive status in schizophrenia patients taking clozapine or risperidone. *J Clin Psychiatry* 1998;59:184–188
64. Farde L, Nyberg S, Oxenstierna G, et al. Positron emission tomography studies on D₂ and 5-HT₂ receptor binding in risperidone-treated schizophrenic patients. *J Clin Psychopharmacol* 1995;15(suppl 1):19S–23S
65. Zayas EM, Grossberg GT. Treatment of psychosis in late life. *J Clin Psychiatry* 1998;59(suppl 1):5–10
66. Daniel DG, Whitcomb SR. Treatment of the refractory schizophrenic patient. *J Clin Psychiatry* 1998;59(suppl 1):13–19
67. Coryell W. The treatment of psychotic depression. *J Clin Psychiatry* 1998;59(suppl 1):22–27
68. Coccaro EF. Clinical outcome of psychopharmacologic treatment of borderline and schizotypal personality disordered subjects. *J Clin Psychiatry* 1998;59(suppl 1):30–35
69. Tohen M, Zarate CA Jr. Antipsychotic agents and bipolar disorder. *J Clin Psychiatry* 1998;59(suppl 1):38–48
70. Schulz SC, Findling RL, Friedman L, et al. Treatment and outcomes in adolescents with schizophrenia. *J Clin Psychiatry* 1998;59(suppl 1):50–54
71. Hillard JR. Emergency treatment of acute psychosis. *J Clin Psychiatry* 1998;59(suppl 1):57–60
72. Masand PS. Weight gain associated with atypical antipsychotics. *J Psychotic Disord* 1998;2:4–6
73. Stahl SM. How to appease the appetite of psychotropic drugs [BRAINSTORMS]. *J Clin Psychiatry* 1998;59:500–501
74. Stahl SM. Neuropharmacology of obesity: my receptors made me eat it [BRAINSTORMS]. *J Clin Psychiatry* 1998;59:447–448
75. Wirshing DA, Marder SR, Goldstein D, et al. Novel antipsychotics: comparison of weight gain liabilities. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology; Dec 8–12, 1997; Kamuela, Hawaii
76. Doss FW. The effect of antipsychotic drugs on body weight: a retrospective review. *J Clin Psychiatry* 1979;40:528–530
77. Allison DB, Mentore JL, Heo MS, et al. Weight gain associated with conventional and newer antipsychotics: a meta-analysis. *Eur Psychiatry* 1998;13:302s
78. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT_{2C} serotonin receptors. *Nature* 1995;374:542–546
79. Findling RL, Grcevich SJ, Lopez I, et al. Antipsychotic medications in children and adolescents. *J Clin Psychiatry* 1996;57(suppl 9):19–23
80. Goldberg TE, Weinberger DR. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. *J Clin Psychiatry* 1996;57(suppl 9):62–65
81. Harvey PD, Keefe RS. Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. *CNS Spectrums* 1997;2:41–55
82. Keck PE Jr, McElroy SL, Strakowski SM. New developments in the pharmacological treatment of schizoaffective disorder. *J Clin Psychiatry* 1996;57(suppl 9):41–48
83. Keck PE, McElroy SL, Strakowski SM, et al. Pharmacological treatment of schizoaffective disorder. *Psychopharmacology (Berl)* 1994;114:529–538
84. McGurk SR, Green MF, Wirshing WC, et al. The effects of risperidone vs haloperidol on cognitive functioning in treatment resistant schizophrenia: the Trail Making Test. *CNS Spectrums* 1997;2(8):60–64
85. Leysen JE, Janssen PMF, Megens AHHP, et al. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacological activity. *J Clin Psychiatry* 1994;55(5, suppl):5–12
86. Marder SR. Facilitating compliance with antipsychotic medication. *J Clin Psychiatry* 1998;59(suppl 3):21–25

87. Nyberg S, Farde L, Eriksson L, et al. 5HT₂ and D₂ dopamine receptor occupancy in the living human brain: a PET study with risperidone. *Psychopharmacology (Berl)* 1993;110:265–272
88. Owens DGC. Extrapyramidal side effects and tolerability of risperidone: a review. *J Clin Psychiatry* 1994;55(5, suppl):29–35
89. Schooler NR. Negative symptoms in schizophrenia: assessment of the effect of risperidone. *J Clin Psychiatry* 1994;55(5, suppl):22–28
90. Sciolla A, Jeste DV. Use of antipsychotics in the elderly. *Int J Psychiatry Clin Pract* 1998;2(suppl 1):S27–S36
91. Sunderland T. Treatment of the elderly suffering from psychosis and dementia. *J Clin Psychiatry* 1996;57(suppl 9):53–56
92. Nyberg S, Farde L, Halldin C. A PET study of 5HT₂ and D₂ dopamine receptor occupancy induced by olanzapine in healthy subjects. *Neuropsychopharmacology* 1997;16:1–7
93. Crawford AM, Beasley CM, Tollefson GD. The acute and long term effects of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. *Schizophr Res* 1997;26:41–54
94. Kinon BJ, Basson B, Tollefson GD. Gender-specific prolactin response to treatment with olanzapine versus risperidone in schizophrenia. In: *New Research Program and Abstracts of the 151st Annual Meeting of the American Psychiatric Association*; June 3, 1998; Toronto, Ontario, Canada. Abstract NR449:189
95. Beuzen J-N, Birkett MA, Kiesler GM, et al. Olanzapine vs clozapine: a double-blind international study in the treatment of resistant schizophrenic patients. Presented at the 37th annual meeting of the American College of Neuropsychopharmacology; Dec 13–18, 1998; Las Croabas, Puerto Rico
96. Shelton R, Tollefson G, Tohen M, et al. The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features. Presented at the 38th annual meeting of the New Clinical Drug Evaluation Unit; June 10–13, 1998; Boca Raton, Fla
97. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind fixed-dose olanzapine trial. *Psychopharmacology (Berl)* 1996;124:159–167
98. Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. *J Clin Psychiatry* 1997;58(suppl 10):7–12
99. Tollefson GD, Beasley CM Jr, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. *Am J Psychiatry* 1997;154:1248–1254
100. Pilowsky LS, Busatto GF, Taylor M, et al. Dopamine D₂ receptor occupancy in vivo by the novel atypical antipsychotic olanzapine: a ¹²³I IBZM single photon emission tomography (SPET) study. *Psychopharmacology (Berl)* 1996;124:148–153
101. Tollefson GD, Tran PV. Reply to Kasper and Kufferle [letter]. *J Clin Psychopharmacol* 1998;18:354–355
102. Tollefson GD, Tran PV. Reply to Gheuens and Grebb [letter]. *J Clin Psychopharmacol* 1998;18:177–178
103. Tollefson GD, Tran PV. Reply to Schooler NR [letter]. *J Clin Psychopharmacol* 1998;18:175–176
104. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. *Am J Psychiatry* 1997;154:457–465
105. Tollefson GD, Sanger TM, Beasley CM, et al. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. *Biol Psychiatry* 1998;43:803–810
106. Tran PV, Dellva MA, Tollefson GD, et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. *J Clin Psychiatry* 1997;58:205–211. Correction 1997;58:275
107. Tran PV, Hamilton SH, Kuntz AJ, et al. Double blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. *J Clin Psychopharmacol* 1997;17:407–418
108. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. *Neuropsychopharmacology* 1996;14:87–96
109. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment resistant schizophrenia. *Am J Psychiatry* 1998;155:914–920
110. Gheuens J, Grebb JA. Comments on article by Tran and associates, “Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders.” *J Clin Psychopharmacol* 1998;18:176–177
111. Glazer WM. Olanzapine and the new generation of antipsychotic agents: patterns of use. *J Clin Psychiatry* 1997;58(suppl 10):18–21
112. Hamilton SH, Revicki DA, Genduso LA, et al. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. *Neuropsychopharmacology* 1998;18:41–49
113. Kasper S, Kufferle B. Comments on “Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders” by Tran and associates. *J Clin Psychopharmacol* 1998;18:353–354
114. Li X-M, Perry KW, Wong DT, et al. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. *Psychopharmacology (Berl)* 1998;136:153–161
115. Littrell KH, Johnson CG, Littrell S, et al. Marked reduction of tardive dyskinesia with olanzapine. *Arch Gen Psychiatry* 1998;55:279–280
116. Martin J, Gomez JC, Garcia-Bernardo E, et al. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. *J Clin Psychiatry* 1997;58:479–483
117. Purdon SE. Olanzapine vs risperidone vs haloperidol in early illness schizophrenia. Presented at the 151st annual meeting of the American Psychiatric Association; 1998; Toronto, Ontario, Canada
118. Ring BJ, Binkley SN, Vandenbranden M, et al. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C19, CYP2D6 and CYP3A. *Br J Clin Pharmacol* 1996;41:181–186
119. Robertson GS, Fibiger HC. Effects of olanzapine on regional CFOS expression in the rat forebrain. *Neuropsychopharmacology* 1996;14:105–110
120. Robertson GS, Fibiger HC. Neuroleptics increase CFOS expression in the forebrain: contrasting effects of haloperidol and clozapine. *Neuroscience* 1992;46:325–328
121. Robertson GS, Matsumura H, Fibiger HC. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. *J Pharmacol Exp Ther* 1994;271:1058–1066
122. Schooler NR. Comments on article by Tran and colleagues, “Double blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders.” *J Clin Psychopharmacol* 1998;18:174–175
123. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. *Neuropsychopharmacology* 1996;14:97–104
124. Street J, Mitan S, Tamura R, et al. Olanzapine in the treatment of psychosis and behavioral disturbances associated with Alzheimer’s disease. Presented at the 3rd Congress of the European Federation of Neurological Societies; Sept 19–25, 1998; Seville, Spain
125. Street JS, Tamura RN, Sanger TM, et al. A comparison of the incidence of long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol. Presented at the 36th annual meeting of the New Clinical Drug Evaluation Unit; June 2, 1996; Boca Raton, Fla
126. Taylor D, Drummond S, Pendlebury J. Olanzapine in practice. *Psychiatr Bull* 1998;22:552–554
127. Zarate CA Jr, Narendran R, Tohen M, et al. Clinical predictors of acute response with olanzapine in psychotic mood disorders. *J Clin Psychiatry* 1998;59:24–28
128. Arvanitis LA, Rak IW. Efficacy, safety and tolerability of Seroquel (quetiapine) in elderly subjects with psychotic disorder. Presented at the 151st annual meeting of the American Psychiatric Association; June 4, 1998; Toronto, Ontario, Canada
129. Gefvert O, Berstrom M, Langstrom B, et al. Time course of central nervous dopamine-D₂ and 5-HT₂ receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. *Psychopharmacology (Berl)* 1998;135:119–126
130. Borison RL, Arvanitis LA, Miller BG, and the US Seroquel Study Group. ICI 205,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. *J Clin Psychopharmacol* 1996;16:158–169
131. King DJ, Link CGG, Kowalczyk B. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. *Psychopharmacology (Berl)* 1998;137:139–146
132. McConville B, Arvanitis L, Wong J, et al. Pharmacokinetics, tolerability and clinical effectiveness of quetiapine fumarate in adolescents with selected psychotic disorders. Presented at the 151st annual meeting of the American Psychiatric Association; June 4, 1998; Toronto, Ontario, Canada

133. Kufferle B, Tauscher J, Asenbaum S, et al. IBZM SPECT imaging of striatal dopamine 2 receptors in psychotic patients treated with a novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. *Psychopharmacology (Berl)* 1997;133:323–328
134. Meats P. Quetiapine (Seroquel): an effective and well tolerated atypical antipsychotic. *Int J Psychiatry Clin Pract* 1997;1:231–239
135. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. *Acta Psychiatr Scand* 1997;96:265–273
136. Sax KW, Strakowski SM, Keck PE Jr. Attentional improvement following quetiapine fumarate treatment in schizophrenia. *Schizophr Res* 1998;33:151–155
137. Small JG, Hirsch SR, Arvanitis LA, et al, and the Seroquel Study Group. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. *Arch Gen Psychiatry* 1997;54:549–557
138. Al-Jeshi A, Jeffries JJ, Kapur S. Loxapine: an enigma. *Can J Psychiatry* 1996;41:131–132
139. Bishop MP, Simpson GM, Dunnett CW, et al. Efficacy of loxapine in the treatment of paranoid schizophrenia. *Psychopharmacology (Berl)* 1977;51:107–115
140. Branchey MH, Lee JH, Simpson GM, et al. Loxapine succinate as a neuroleptic agent: evaluation in two populations of elderly psychiatric patients. *J Am Geriatr Soc* 1978;26:263–267
141. Carlyle W, Ancill RJ, Sheldon L. Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. *Int Clin Psychopharmacol* 1993;8:103–108
142. Charalampous KD, Freemeser GF, Malev J, et al. Loxapine succinate: a controlled double-blind study in schizophrenia. *Curr Ther Res* 1974;16:829–837
143. Cheung SW, Tang SW, Remington G. Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography. *J Chromatogr* 1991;564:213–221
144. Cohen BM, Harris PQ, Altesman RI, et al. Amoxapine: neuroleptic as well as antidepressant? *Am J Psychiatry* 1982;139:1165–1167
145. Cole JO, Swett C, Campbell C, et al. Parenteral and oral Loxitane in the treatment of schizophrenic disorders. *Curr Ther Res* 1982;31:656–661
146. Coupet J, Szues-Myers VA, Greenblatt EN. The effects of 2-chloro-11-(4-methyl-1-piperazinyl)-dibenz [b,f] {1,4}oxazepine (loxapine) and its derivatives on the dopamine-sensitive adenylate cyclase of rat striatal homogenates. *Brain Res* 1976;116:177–180
147. Coupet J, Rauh CE, Szues-Myers VA, et al. 2-chloro-11-(1-piperazinyl) dibenz [b,f] {1,4}oxazepine (amoxapine), an antidepressant with antipsychotic properties: a possible role for 7-hydroxyamoxapine. *Biochem Pharmacol* 1979;28:2514–2515
148. Coupet J, Rauh CE. ³H-spiroperidol binding to dopamine receptors in rat striatal membranes: influence of loxapine and its hydroxylated metabolites. *Eur J Pharmacol* 1979;55:215–218
149. Dahl SG. Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. *Ther Drug Monit* 1982;4:33–40
150. Dean GA, Gallant DM. Intramuscular loxapine (Loxitane): rapid tranquilization of acutely disturbed schizophrenic patients. *Curr Ther Res* 1979;25:721–725
151. Deniker P, Loo H, Cottureau MJ. Parenteral loxapine in severely disturbed schizophrenic patients. *J Clin Psychiatry* 1980;41:23–26
152. DePaulo JR Jr, Ayd FJ Jr. Loxapine: fifteen years' clinical experience. *Psychosomatics* 1982;23:261–271
153. Dubin WR, Weiss KJ. Rapid tranquilization: a comparison of thiothixene with loxapine. *J Clin Psychiatry* 1986;47:294–297
154. Filho UV, Caldeira VV, Bueno JR. The efficacy and safety of loxapine succinate in the treatment of schizophrenia: a comparative study with thiothixene. *Curr Ther Res* 1975;18:476–490
155. Fruensgaard K, Jensen K. Treatment of acute psychotic patients with loxapine parenterally. *Curr Ther Res* 1976;19:164–169
156. Fruensgaard K, Korsgaard S, Jorgensen H, et al. Loxapine versus haloperidol parenterally in acute psychosis with agitation. *Acta Psychiatr Scand* 1977;56:256–264
157. Fulton A, Norman T, Burrows GD. Ligand binding and platelet uptake studies of loxapine, amoxapine and their 8 hydroxylated derivatives. *J Affect Disord* 1982;4:113–119
158. Hue B, Palomba B, Giacardy-Paty M, et al. Concurrent high-performance liquid chromatographic measurement of loxapine and amoxapine and of their hydroxylated metabolites in plasma. *Ther Drug Monit* 1998;20:335–339
159. Kapur S, Zipursky RB, Jones C, et al. The D₂ receptor occupancy profile of loxapine determined using PET. *Neuropsychopharmacology* 1996;15:562–566
160. Kapur S, Zipurski R, Remington G, et al. PET evidence that loxapine is an equipotent blocker of 5-HT₂ and D₂ receptors: implications for the therapeutics of schizophrenia. *Am J Psychiatry* 1997;154:1525–1529
161. Kiloh LG, Williams SE, Grant DA, et al. A double-blind comparative trial of loxapine and trifluoperazine in acute and chronic schizophrenic patients. *J Int Med Res* 1976;4:441–448
162. Kramer M, Roth T, Salis PJ, et al. Relative efficacy and safety of loxapine succinate (Loxitane) and thioridazine hydrochloride (Mellaril) in the treatment of acute schizophrenia. *Curr Ther Res* 1978;23:619–631
163. Lehmann CR, Ereshefsky L, Saklad SR, et al. Very high dose loxapine in refractory schizophrenic patients. *Am J Psychiatry* 1981;138:1212–1214
164. Leone NF. Open evaluation of loxapine succinate (Loxitane) in the treatment of acutely ill schizophrenic outpatients. *Curr Ther Res* 1979;26:515–524
165. Midha KK, Hubbard JW, McKay G, et al. The role of metabolites in a bioequivalence study 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. *Int J Clin Pharmacol Ther Toxicol* 1993;31:177–183
166. Mowerman S, Siris SG. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. *Ann Clin Psychiatry* 1996;8:193–197
167. Moyano CZ. A double-blind comparison of Loxitane (loxapine succinate) and trifluoperazine hydrochloride in chronic schizophrenic patients. *Dis Nerv Syst* 1975;36:301–304
168. O'Connell RA, Lieberman JA. Parenteral loxapine in acute schizophrenia. *Curr Ther Res* 1978;23:236–242
169. Paprocki J, Versiani M. A double blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. *Curr Ther Res* 1977;21:80–100
170. Paprocki J, Barcala Peixoto MP, Mendes Andrade N. A controlled double-blind comparison between loxapine and haloperidol in acute newly hospitalized schizophrenic patients. *Psychopharmacol Bull* 1976;12:32–34
171. Robertson AG, Berry R, Meltzer HY. Prolactin stimulating effects of amoxapine and loxapine in psychiatric patients. *Psychopharmacology (Berl)* 1982;78:287–292
172. Schiele BC. Loxapine succinate: a controlled double-blind study in chronic schizophrenia. *Dis Nerv Syst* 1975;36:361–364
173. Selkin J. Loxitane-C (loxapine succinate) oral liquid concentrate in the rapid tranquilization of acutely disturbed schizophrenic patients. *Curr Ther Res* 1979;26:908–919
174. Selman FB, McClure RF, Helwig H. Loxapine succinate: a double blind comparison with haloperidol and placebo in acute schizophrenics. *Curr Ther Res* 1976;19:645–652
175. Serban G. Loxapine in acute schizophrenic disorder. *Curr Ther Res* 1979;25:139–143
176. Simpson GM, Cooper TB, Lee H, et al. Clinical and plasma level characteristics of intramuscular and oral loxapine. *Psychopharmacology (Berl)* 1978;56:225–232
177. Singh AN, Barlas C, Singh S, et al. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D₁, D₂, D₃ and serotonin 5HT₂ receptor subtypes. *J Psychiatry Neurosci* 1996;21:29–35
178. Thomas JL. Loxapine oral liquid concentrate in the treatment of young adult patients with acute schizophrenic symptoms. *Curr Ther Res* 1979;25:371–377
179. Tuason VB, Escobar JJ, Garvey M, et al. Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study. *J Clin Psychiatry* 1984;45:158–163
180. Tuason VB. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. *J Clin Psychiatry* 1986;47:126–129
181. Van der Velde CD. Effectiveness of loxapine succinate in acute schizophrenia: a comparative study with thiothixene. *Curr Ther Res* 1975;17:1–12
182. Zisook S, Devaul R, Jaffe K, et al. Loxapine succinate (Loxitane) in the outpatient treatment of acutely ill schizophrenic patients. *Curr Ther Res* 1978;24:415–426
183. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. *J Clin Psychiatry* 1999;60(suppl 10):20–30
184. Meltzer HY, Jayathilake K. Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine? *J Clin Psychiatry* 1999;60(suppl 10):47–51